Clinical trial · Observational
The Role of Inflammation in Ocular Tumours
NCT02909517CI-TRIAL-00038765unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective, non-therapeutic study will determine whether a novel imaging technique can identify presumptive tumour associated macrophages (TAMs) in patients with ocular tumours. The investigators will evaluate 5 groups: 1. Choroidal nevus 2. Choroidal indeterminate melanocytic lesion 3. Choroidal melanoma 4. Suspected metastatic tumour (ie, primary tumour elsewhere) 5. Locally treated ocular tumours
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ocular Melanoma | Ocular Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cSLO imaging | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- label
- Choroidal nevus
- description
- Requires distinction from melanoma through diagnostic testing (low-risk features)
- interventionNames
- Other: cSLO imaging
- label
- Choroidal indeterminate melanocytic lesion
- description
- Requires diagnostic testing for identification and distinction from nevus and melanoma (high-risk features)
- interventionNames
- Other: cSLO imaging
- label
- Choroidal melanoma
- description
- Requires confirmation of diagnosis and evaluation for potential metatstases
- interventionNames
- Other: cSLO imaging
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Any tentative clinical diagnosis of: 1. Choroidal nevus (low-risk features): 2. Choroidal indeterminate melanocytic lesion (high-risk features) 3. Choroidal melanoma 4. Suspected metastatic tumour (ie, primary tumour elsewhere) 5. Locally treated ocular tumours Note that a patient can enroll in this study twice, once before treatment and once after, provided that at least one month has passed since initiation of treatment. This patient will count twice (ie, once in each of two study arms) Male and female age 18 years and older Ability to provide informed consent Exclusion Criteria: * Allergy to angiography dye * Cases that do not meet the above criteria for tumor size will be ineligible to participate in the study. * Patients not able to provide consent for the study. * Patients with a poor view of the fundus due to cataract or vitreous hemorrhage. * Patients \< 18 years of age. Any concurrent unrelated eye diagnosis
References
Publications (0)
Data not yet available
No reference posted for this study.